USD
$0.00
(0.00%
)At Close (As of Sep 5, 2025)
$252.56B
Market Cap
14.32
P/E Ratio
3.92
EPS
$134.51
52 Week High
$44.55
52 Week Low
HEALTHCARE
Sector
Field | Value (DKK) |
---|---|
Gross Profit | $246B |
Total Revenue | $290B |
Cost Of Revenue | $45B |
Costof Goods And Services Sold | $45B |
Operating Income | $128B |
Selling General And Administrative | $5.3B |
Research And Development | $48B |
Operating Expenses | $118B |
Investment Income Net | - |
Net Interest Income | -$91M |
Interest Income | $1.8B |
Interest Expense | $1.6B |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $8.5B |
Income Before Tax | $127B |
Income Tax Expense | $26B |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $101B |
Comprehensive Income Net Of Tax | - |
Ebit | $129B |
Ebitda | $137B |
Net Income | $101B |
Field | Value (DKK) |
---|---|
Total Assets | $466B |
Total Current Assets | $161B |
Cash And Cash Equivalents At Carrying Value | $16B |
Cash And Short Term Investments | $16B |
Inventory | $41B |
Current Net Receivables | $87B |
Total Non Current Assets | $305B |
Property Plant Equipment | $162B |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $91B |
Intangible Assets Excluding Goodwill | $91B |
Goodwill | $20B |
Investments | - |
Long Term Investments | $2.7B |
Short Term Investments | $11B |
Other Current Assets | $6.3B |
Other Non Current Assets | - |
Total Liabilities | $322B |
Total Current Liabilities | $218B |
Current Accounts Payable | $29B |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $13B |
Total Non Current Liabilities | $105B |
Capital Lease Obligations | $6.8B |
Long Term Debt | $84B |
Current Long Term Debt | $12B |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $103B |
Other Current Liabilities | $166B |
Other Non Current Liabilities | $23M |
Total Shareholder Equity | $143B |
Treasury Stock | - |
Retained Earnings | $144B |
Common Stock | $446M |
Common Stock Shares Outstanding | $4.5B |
Field | Value (DKK) |
---|---|
Operating Cashflow | $121B |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $8.5B |
Capital Expenditures | $51B |
Change In Receivables | - |
Change In Inventory | -$9B |
Profit Loss | - |
Cashflow From Investment | -$129B |
Cashflow From Financing | $8.7B |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | $44B |
Dividend Payout Common Stock | $44B |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$20B |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $101B |
Field | Value (DKK) |
---|---|
Gross Profit | $246B |
Total Revenue | $290B |
Cost Of Revenue | $45B |
Costof Goods And Services Sold | $45B |
Operating Income | $128B |
Selling General And Administrative | $5.3B |
Research And Development | $48B |
Operating Expenses | $118B |
Investment Income Net | - |
Net Interest Income | -$91M |
Interest Income | $1.8B |
Interest Expense | $1.6B |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $8.5B |
Income Before Tax | $127B |
Income Tax Expense | $26B |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $101B |
Comprehensive Income Net Of Tax | - |
Ebit | $129B |
Ebitda | $137B |
Net Income | $101B |
Field | Value |
---|---|
Ex Dividend Date | 2025-08-18 |
Declaration Date | 2025-08-06 |
Record Date | 2025-08-18 |
Payment Date | 2025-08-26 |
Amount | 0.584816 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.